Epigenetics in rare neurological diseases

Front Cell Dev Biol. 2024 Jul 23:12:1413248. doi: 10.3389/fcell.2024.1413248. eCollection 2024.

Abstract

Rare neurological diseases include a vast group of heterogenous syndromes with primary impairment(s) in the peripheral and/or central nervous systems. Such rare disorders may have overlapping phenotypes, despite their distinct genetic etiology. One unique aspect of rare neurological diseases is their potential common association with altered epigenetic mechanisms. Epigenetic mechanisms include regulatory processes that control gene expression and cellular phenotype without changing the composition of the corresponding DNA sequences. Epigenetic factors include three types of proteins, the "readers, writers, and erasers" of DNA and DNA-bound proteins. Thus, epigenetic impairments of many neurological diseases may contribute to their pathology and manifested phenotypes. Here, we aim to provide a comprehensive review on the general etiology of selected rare neurological diseases, that include Rett Syndrome, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Huntington's disease, and Angelman syndrome, with respect to their associated aberrant epigenetic mechanisms.

Keywords: Angelman Syndrome; DNA methylation; MeCP2; Prader-Willi Syndrome; Rett Syndrome; epigenetics; histone modifications; rare neurological diseases.

Publication types

  • Review

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work is supported by funds from the Canadian Institutes of Health Research (CIHR) Project Grant 202209PJT-486512-CIA-CDAA-111824 to MR and JRD, the Ontario Rett Syndrome Association (ORSA) Hope Fund to MR, the Children’s Hospital Research Institute of Manitoba (CHRIM) Operating Grant to MR, and the University of Manitoba Collaborative Research Program (UCRP) to MR.